The Protective Role of Interleukin-37 in Cardiovascular Diseases Through Ferroptosis Modulation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 28

PMID 39337246

Authors

Alfredo Cruz-Gregorio

Luis M Amezcua-Guerra

Brandon Fisher-Bautista

Abraham Romero-Beltran

Gabriela Fonseca-Camarillo

Affiliations

Soon will be listed here.

Abstract

The role of ferroptosis and iron metabolism dysregulation in the pathophysiology of cardiovascular diseases is increasingly recognized. Conditions such as hypertension, cardiomyopathy, atherosclerosis, myocardial ischemia/reperfusion injury, heart failure, and cardiovascular complications associated with COVID-19 have been linked to these processes. Inflammation is central to these conditions, prompting exploration into the inflammatory and immunoregulatory molecular pathways that mediate ferroptosis and its contribution to cardiovascular disease progression. Notably, emerging evidence highlights interleukin-37 as a protective cytokine with the ability to activate the nuclear factor erythroid 2-related factor 2 pathway, inhibit macrophage ferroptosis, and attenuate atherosclerosis progression in murine models. However, a comprehensive review focusing on interleukin-37 and its protective role against ferroptosis in CVD is currently lacking. This review aims to fill this gap by summarizing existing knowledge on interleukin-37, including its regulatory functions and impact on ferroptosis in conditions such as atherosclerosis and myocardial infarction. We also explore experimental strategies and propose that targeting interleukin-37 to modulate ferroptosis presents a promising therapeutic approach for the prevention and treatment of cardiovascular diseases.

References

Law C, Puranik R, Fan J, Fei J, Hambly B, Bao S . Clinical Implications of IL-32, IL-34 and IL-37 in Atherosclerosis: Speculative Role in Cardiovascular Manifestations of COVID-19. Front Cardiovasc Med. 2021; 8:630767. PMC: 8377289. DOI: 10.3389/fcvm.2021.630767. View

Fang X, Ardehali H, Min J, Wang F . The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2022; 20(1):7-23. PMC: 9252571. DOI: 10.1038/s41569-022-00735-4. View

Gagliardi M, Cotella D, Santoro C, Cora D, Barlev N, Piacentini M . Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis. 2019; 10(12):902. PMC: 6883066. DOI: 10.1038/s41419-019-2143-7. View

Jiang X, Stockwell B, Conrad M . Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282. PMC: 8142022. DOI: 10.1038/s41580-020-00324-8. View

Colakoglu M, Tuncer S, Banerjee S . Emerging cellular functions of the lipid metabolizing enzyme 15-Lipoxygenase-1. Cell Prolif. 2018; 51(5):e12472. PMC: 6528901. DOI: 10.1111/cpr.12472. View

Lotfy H, Moaaz M, Moaaz M . The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis. Vascular. 2020; 28(5):629-642. DOI: 10.1177/1708538120921735. View

Agborbesong E, Li L, Li L, Li X . Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD. Front Mol Biosci. 2022; 9:922428. PMC: 9277309. DOI: 10.3389/fmolb.2022.922428. View

Martins R, Knapp S . Heme and hemolysis in innate immunity: adding insult to injury. Curr Opin Immunol. 2017; 50:14-20. DOI: 10.1016/j.coi.2017.10.005. View

Belcher J, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash A . Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2013; 123(3):377-90. PMC: 3894494. DOI: 10.1182/blood-2013-04-495887. View

10.

Lai Y, Dong C . Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol. 2015; 28(4):181-8. PMC: 4889878. DOI: 10.1093/intimm/dxv063. View

11.

de Jonge H, Dekkers D, Lamers J . Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. Mol Cell Biochem. 1996; 157(1-2):199-210. DOI: 10.1007/BF00227899. View

12.

Dinarello C, Nold-Petry C, Nold M, Fujita M, Li S, Kim S . Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol. 2016; 46(5):1067-81. PMC: 5003108. DOI: 10.1002/eji.201545828. View

13.

Ru Y, Luo Y, Liu D, Huang Q, Zhou X, Linghu M . Isorhamnetin alleviates ferroptosis-mediated colitis by activating the NRF2/HO-1 pathway and chelating iron. Int Immunopharmacol. 2024; 135:112318. DOI: 10.1016/j.intimp.2024.112318. View

14.

Tesfay L, Paul B, Konstorum A, Deng Z, Cox A, Lee J . Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death. Cancer Res. 2019; 79(20):5355-5366. PMC: 6801059. DOI: 10.1158/0008-5472.CAN-19-0369. View

15.

Liang J, Jin X, Zhang S, Huang Q, Ji P, Deng X . Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Sci Bull (Beijing). 2023; 68(6):622-636. DOI: 10.1016/j.scib.2023.02.027. View

16.

Gong T, Liu L, Jiang W, Zhou R . DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2019; 20(2):95-112. DOI: 10.1038/s41577-019-0215-7. View

17.

Couillin I, Riteau N . STING Signaling and Sterile Inflammation. Front Immunol. 2021; 12:753789. PMC: 8517477. DOI: 10.3389/fimmu.2021.753789. View

18.

Yu K, Min X, Lin Y, Huang Y, Huang S, Liu L . Increased IL-37 concentrations in patients with arterial calcification. Clin Chim Acta. 2016; 461:19-24. DOI: 10.1016/j.cca.2016.07.011. View

19.

Lopez-Bautista F, Posadas-Sanchez R, Vazquez-Vazquez C, Fragoso J, Rodriguez-Perez J, Vargas-Alarcon G . IL-37 Gene and Cholesterol Metabolism: Association of Polymorphisms with the Presence of Hypercholesterolemia and Cardiovascular Risk Factors. The GEA Mexican Study. Biomolecules. 2020; 10(10). PMC: 7601011. DOI: 10.3390/biom10101409. View

20.

Schillemans M, Karampini E, Kat M, Bierings R . Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit. J Thromb Haemost. 2018; 17(1):6-18. PMC: 7379738. DOI: 10.1111/jth.14322. View